Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15483041 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1ALOX15RECQL | |
| SCHEMBL1679735 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1ALOX15RECQL | |
| SCHEMBL1679732 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1ALOX15RECQL | |
| SCHEMBL11576798 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1ALOX15RECQL | |
| SCHEMBL2616617 | 1.00 | ALDH1A1 (0.42) | ALDH1A1TSHRTDP1ALOX15RECQL | |
| SCHEMBL12976498 | 0.91 | — | — | |
| SCHEMBL2919091 | 0.91 | TSHR (0.37) | ALDH1A1TSHRTDP1ALOX15RECQL | |
| SCHEMBL6649326 | 0.91 | TSHR (0.37) | ALDH1A1TSHRTDP1ALOX15RECQL | |
| SCHEMBL2616645 | 0.88 | ALDH1A1 (0.58) | ALDH1A1TSHRTDP1ALOX15RECQL | |
| SCHEMBL5074195 | 0.88 | ALDH1A1 (0.58) | ALDH1A1TSHRTDP1ALOX15RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116496150-B | Preparation method of 2, 7-dimethyl-2, 4, 6-octatriene-1, 8-dialdehyde | 万华化学集团股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-116199570-B | Preparation method of 2, 7-dimethyl-2, 4, 6-octatriene-1, 8-dialdehyde | 万华化学集团股份有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-115385781-B | Method for preparing 1, 4-tetraalkoxy-2-butene compound | 万华化学集团股份有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117777493-A | Conductive hydrogel, preparation method and electrode plate prepared by using conductive hydrogel | 上海英科心电图医疗产品有限公司 | 2024-03-29 | — | — | CN | disclosed |
| CN-116730888-A | Preparation method and application of canthaxanthin | 万华化学集团股份有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-116496150-A | Preparation method of 2, 7-dimethyl-2, 4, 6-octatriene-1, 8-dialdehyde | 万华化学集团股份有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116199570-A | Preparation method of 2, 7-dimethyl-2, 4, 6-octatriene-1, 8-dialdehyde | 万华化学集团股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-115385781-A | Method for preparing 1, 4-tetraalkoxy-2-butene compound | 万华化学集团股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-108752178-B | Preparation method of 2, 7-dimethyl-2, 4, 6-octatriene-1, 8-dialdehyde | 万华化学集团股份有限公司 | 2021-04-20 | — | — | CN | disclosed |
| US-20170202798-A1 | BIPOLAR TRANS CARTENOID SALTS AND THEIR USES | DIFFUSION PHARMACEUTICALS LLC (US) | 2017-07-20 | — | — | US | disclosed |
| US-7759506-B2 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-7759506-B2 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2010-07-20 | — | — | US | disclosed |
| US-20100137436-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137436-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2010-06-03 | — | — | US | disclosed |
| US-7351844-B2 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2008-04-01 | — | — | US | disclosed |
| US-7351844-B2 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2008-04-01 | — | — | US | disclosed |
| US-20070203353-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070203353-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2007-08-30 | — | — | US | disclosed |
| US-20070161610-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161610-A1 | Bipolar trans carotenoid salts and their uses | DIFFUSION PHARMACEUTICALS LLC (US) | 2007-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203353-A1 | Bipolar trans carotenoid salts and their uses | RBP4, MB, SLC6A12 | ALDH1A1 3199/4885TSHR 1232/4885TDP1 2317/4885 |
| US-20100137436-A1 | Bipolar trans carotenoid salts and their uses | RBP4, MB, SLC6A12 | ALDH1A1 3199/4885TSHR 1232/4885TDP1 2317/4885 |
| US-20070161610-A1 | Bipolar trans carotenoid salts and their uses | RBP4, MB, SLC6A12 | ALDH1A1 3199/4885TSHR 1232/4885TDP1 2317/4885 |
| US-20170202798-A1 | BIPOLAR TRANS CARTENOID SALTS AND THEIR USES | TXNRD2, CYP11B2, CYP11B1 | ALDH1A1 2608/4885TSHR 1403/4885TDP1 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.